Non-invasive diagnosis and biomarkers in alcohol-related liver disease

Clinical Manifestations and Diagnosis of Non-Alcoholic Fatty Liver Disease

Background & Objective: Nonalcoholic fatty liver diseases (NAFLD) is the major cause of hepatocellular carcinoma and increases the risk of mortality. Understanding the trends of its clinical and biochemical changes is essential to identify patients with NAFLD that are at the greatest risk of nonalcoholic steatohepatitis (NASH) and cirrhosis in Iran. M...

Simple non-invasive biomarkers of advanced fibrosis in the evaluation of non-alcoholic fatty liver disease

BACKGROUND AND AIMS Non-alcoholic fatty liver disease (NAFLD) is a common, morbid disease with profound implications for the overall health of the patient. We set out to determine the clinical predictors of advanced histology in the referral population. METHODS We performed a retrospective review of all biopsy-proven NAFLD patients, including 358 unique patients first seen between 1996 and 20...

Non-Invasive Biomarkers vs Liver Biopsy in Diagnosing & Staging NAFLD

Introduction: Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of disease ranging from simple steatosis to inflammatory steatohepatitis (NASH) with increasing levels of fibrosis and ultimately cirrhosis. It has been considered the most common liver disease and the most frequent cause of elevated aminotransferases and cryptogenic cirrhosis. Aims and Objectives: To evaluate the ro...

Serum biomarkers for the non-invasive diagnosis of liver fibrosis: the importance of being validated.

Chronic liver diseases (CLDs), including chronic hepatitis C and B, alcoholic and non-alcoholic fatty liver diseases, represent a major cause of morbidity and mortality worldwide. The progressive accumulation of fi brosis in the liver characterizes the natural history of CLDs and represents the hallmark of the evolution towards hepatic cirrhosis and its end-stage complications (1) . Staging of ...

The Genetics of Alcohol- Related Liver Disease